Dec 05, 2020
Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia
Sep 08, 2020
Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Aug 27, 2020
Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Mar 10, 2020
Sysmex Inostics' Updated SafeSEQ Breast Cancer Panel Advances Novel Clinical Uses of ctDNA Through Quantitative Testing
Mar 09, 2020
/DISREGARD RELEASE: Sysmex Inostics GmbH/
Dec 16, 2019
Sysmex Inostics Announces First Results of Tissue-independent Liquid Biopsy for Early Stage Breast Cancer Mutation Characterization and Monitoring Using Ultra-sensitive SafeSEQ Technology
Sep 04, 2019
Sysmex Inostics Publishes First Feasibility Study of NGS-based Liquid Biopsy to Complement Early Breast Cancer Screening by Imaging
Aug 02, 2019
Sysmex Obtains Japanese Manufacturing and Marketing Approval for the First Blood-based RAS Mutation Testing for Colorectal Cancer
Jul 18, 2019
Liquid Biopsy Performance Comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS Testing Published in Scientific Reports (Nature Journal)
May 30, 2019
Sysmex Inostics OncoBEAM(TM)-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study
May 28, 2019
Sysmex Inostics' SafeSEQ ER+/HER2- Breast Cancer Panel Demonstrates Equivalent Sensitivity to OncoBEAM(TM) Enhanced Digital PCR Technology for Detection of Mutations in Circulating Tumor DNA
Feb 25, 2019
Sysmex Inostics' OncoBEAM(TM) Demonstrates Clinical Validity and Superior Performance Versus Pan-cancer NGS for Blood-based Mutation Detection for Hepatocellular Carcinoma
Nov 05, 2018
Sysmex Inostics OncoBEAM(TM) Circulating Tumor DNA Technology Demonstrates Superior Response Prediction for Advanced Pancreatic Cancer over Standard-of-care Protein Biomarkers
Oct 18, 2018
Sysmex Inostics' OncoBEAM(TM) Platform Demonstrates Superior Detection of Clinically-relevant Mutations for Therapy Selection and Molecular Monitoring for Lung and Colon Cancers
Oct 15, 2018
Sysmex Inostics' OncoBEAM(TM) Liquid Biopsy Technology Demonstrates Utility for Clinical Management of Melanoma Patients Undergoing Treatment With Targeted Therapy and Immune Checkpoint Inhibitors
Sep 28, 2018
Sysmex Inostics Announces Launch of OncoBEAMTM EGFR Kit v2 (RUO) in Europe and Asia
May 31, 2018
Clinical Evaluation of Sysmex Inostics' Plasma NGS Liquid Biopsy Technology to Complement Mammography When Screening for Early Stage Breast Cancer Presented at the 2018 ASCO Annual Meeting
Apr 13, 2018
Sysmex Inostics Expands OncoBEAM(TM) Liquid Biopsy Testing in the U.S. to Assist Clinicians and Patients
Apr 11, 2018
Sysmex Inostics: OncoBEAM(TM) RAS CRC Liquid Biopsy Test Now Reimbursed in Germany by BARMER
Jan 22, 2018
In Depth: Performance Comparison of OncoBEAM(TM) RAS CRC and Idylla(TM) ctKRAS Liquid Biopsy Testing for KRAS Mutation Detection Presented at ASCO GI 2018